Tandem Diabetes Care, Inc. (NASDAQ:TNDM) was up 5.4% during trading on Friday . The stock traded as high as $2.66 and last traded at $2.53. Approximately 1,392,613 shares changed hands during trading, a decline of 7% from the average daily volume of 1,490,980 shares. The stock had previously closed at $2.40.

Several equities research analysts have commented on TNDM shares. Piper Jaffray Companies restated a “hold” rating and set a $15.00 target price on shares of Tandem Diabetes Care in a research report on Friday, October 6th. Zacks Investment Research lowered shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Wedbush restated an “outperform” rating and set a $17.00 target price (down from $50.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 10th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $29.31.

The stock’s market capitalization is $127.08 million. The stock has a 50-day moving average of $5.75 and a 200-day moving average of $7.45.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, July 27th. The medical device company reported ($4.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($4.80) by $0.40. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. The business had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $21.74 million. During the same quarter last year, the business posted ($6.00) earnings per share. The company’s quarterly revenue was down 7.4% on a year-over-year basis. On average, analysts forecast that Tandem Diabetes Care, Inc. will post ($17.06) earnings per share for the current fiscal year.

In other news, CEO Kim D. Blickenstaff bought 285,700 shares of the firm’s stock in a transaction that occurred on Friday, October 13th. The stock was acquired at an average price of $3.50 per share, with a total value of $999,950.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 20.90% of the company’s stock.

A number of hedge funds have recently made changes to their positions in TNDM. Bank of America Corp DE boosted its stake in Tandem Diabetes Care by 88.6% during the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock valued at $1,032,000 after buying an additional 404,452 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Tandem Diabetes Care during the first quarter valued at about $360,000. Keybank National Association OH boosted its stake in Tandem Diabetes Care by 32.7% during the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock valued at $235,000 after buying an additional 72,177 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Tandem Diabetes Care by 2.7% during the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock valued at $987,000 after buying an additional 32,991 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/20/tandem-diabetes-care-inc-tndm-trading-up-5-4.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Receive News & Stock Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related stocks with our FREE daily email newsletter.